ovalicin, 19683-98-8

Articles:

PubMed:	Polyketides from the littoral plant associated fungus Pseudallescheria boydii.
PubMed:	Ovalicin ameliorates compound 48/80-induced atopic dermatitis-related symptoms.
PubMed:	Syntheses of fumagillin and ovalicin.
PubMed:	In vivo activity of cationic immune stimulating complexes (PLUSCOMs).
PubMed:	Total syntheses of (+/-)-ovalicin, C4(S *)-isomer, and its C5-analogs and anti-trypanosomal activities.
PubMed:	A Diels-Alder approach to (-)-ovalicin.
PubMed:	New bioactive sesquiterpenes from Ripartites metrodii and R. tricholoma.
PubMed:	Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase.
PubMed:	Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo.
PubMed:	Methionine aminopeptidase 2 and cancer.
PubMed:	Concise enantio- and diastereoselective total syntheses of fumagillol, RK-805, FR65814, ovalicin, and 5-demethylovalicin.
PubMed:	Synthesis of ovalicin starting from D-mannose.
PubMed:	Structural basis for the functional differences between type I and type II human methionine aminopeptidases.
PubMed:	Investigations into microsporidian methionine aminopeptidase type 2: a therapeutic target for microsporidiosis.
PubMed:	Synthesis and biological evaluation of novel fumagillin and ovalicin analogues.
PubMed:	A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases.
PubMed:	Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.
PubMed:	Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.
PubMed:	Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4.
PubMed:	QSAR of the inhibition of angiogenesis by TNP-470 and ovalicin analogues: another example of an allosteric interaction.
PubMed:	Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.
PubMed:	Structure and function of the methionine aminopeptidases.
PubMed:	Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells.
PubMed:	Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
PubMed:	Mer-f3, 12-hydroxy-ovalicin, produced by Metarrhizium sp. f3.
PubMed:	Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.
PubMed:	Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression.
PubMed:	The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase.
PubMed:	Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.
PubMed:	Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. II. Physicochemical properties and structural elucidation.
PubMed:	Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. I. Taxonomy, fermentation, isolation and biological activities.
PubMed:	The history of cyclosporin A (Sandimmune) revisited: another point of view.
PubMed:	Enhanced toxicity of the immunosuppressant ovalicin upon application to the skin.
PubMed:	On the mode of action of the immunosuppressive sesquiterpene ovalicin.
PubMed:	On the mechanism of action of the cytostatic drug anguidine and of the immunosuppressive agent ovalicin, two sesquiterpenes from fungi.
PubMed:	Application of deuterium magnetic resonance to biosynthetic studies. 1. Biosynthesis of ovalicin.
PubMed:	Application of carbon-13 magnetic resonance to isoprenoid biosynthesis. II. Ovalicin and the use of doubly labeled mevalonate.
PubMed:	Letter: Application of carbon-13 magnetic resonance to isoprenoid biosynthesis. I. Ovalicin.
PubMed:	Immunosuppressive effects of ovalicin-semicarbazone.
PubMed:	[Structure of ovalicin].
PubMed:	Effect of the immunosuppressive agent ovalicin on the kinetics of antibody formation.
PubMed:	Immunosuppressive effect of a new antibiotic: ovalicin.
PubMed:	Immunosuppressive and specific antimitotic effects of ovalicin.
PubMed:	[Isolation and structure elucidation of ovalicin].